Sentence examples for most discontinuation from inspiring English sources

9 Although discontinuation of antipsychotics is advocated in all guidelines and most discontinuation studies did not find a relapse of neuropsychiatric symptoms, 10 one recent study actually found a relapse of neuropsychiatric symptoms.

Withdrawals due to adverse events were evenly distributed throughout the treatment period, whereas previous studies, in which treatment was initiated at doses of 100 mg per day or higher, most discontinuation events occurred during the first two weeks of treatment.

None of the patients receiving TDOXY discontinued treatment due to dry mouth; most discontinuations were because of application site reactions.

Most discontinuations were due to loss to follow-up.

Most discontinuations (19.0% and 27.6%, respectively) were based on patient decision (individual reasons not reported).

The rate of treatment discontinuation was high in both groups, with most discontinuations due to disease progression, and some discontinuations due to adverse events.

Most discontinuations during the double-blind period were due to worsening of fibromyalgia requiring alternative treatment, which was one of the LTR definitions used in this study.

Discontinuation because of AEs occurred in 11 subjects overall (2%) and in 9 subjects in the canagliflozin groups (3%) without apparent relation to dose (Table 2); most discontinuations were for gastrointestinal disorders (5 subjects [1 placebo, 4 canagliflozin], 1%).

Nausea was reported by 59% of patients in the extension trial compared with 36.9% of patients in the current analysis, and most discontinuations due to adverse events were attributed to nausea in both the extension trial and our analysis.

Most discontinuations (n = 25, 40.3 %) were for penitentiary reasons, i.e., release or transfers between prisons; again, there were no differences in this regard between patients with PD and those without (39.5 % vs. 41.7 %; p = 0.86).

The overall rate of discontinuation of sorafenib due to AEs in DECISION was <20%, indicating that in the majority of patients with RAI-refractory DTC the drug was well tolerated, with most discontinuations due to AEs (4%) occurring in cycle 1.